Announcements – Neville Registrars

27 NOVEMBER 2015

Nanoco Group PLC : Lighting Division Update

RNS Number : 1436H Nanoco Group PLC 27 November 2015 For immediate release 27 November 2015 RNS REACH NANOCO GROUP PLC ("Nanoco" or the "Company") Lighting Division Update Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free……

RNS Number : 1436H

Nanoco Group PLC

27 November 2015

For immediate release

27 November 2015

RNS REACH

NANOCO GROUP PLC

("Nanoco" or the "Company")

Lighting Division Update

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, announces the following update on its Lighting Division following the successful launch of the world's first CFQD® Quantum Dot lighting products at the LuxLive industry trade show in London.

Nanoco and its partner Marl International, a UK-based pioneer in LED lighting, launched four product groups at LuxLive including light-emitting ceiling tiles, strip lights, down lighters, and grow lights. All of the product groups use Nanoco CFQD® Quantum Dot film, with the thickness of the film and the size of the quantum dots fine-tuned for specific end uses where colour quality is the primary requirement.

In the run up to last week's LuxLive trade show, Nanoco was highlighted in the Lux Global Hotlist 2015 of the ten most exciting lighting firms worldwide. The Global Hotlist panel's citation described Nanoco as a producer of "cadmium-free quantum dots which promise near perfect colour rendering from LEDs". In addition, the Orion strip light developed with Marl was listed among the "10 product innovations to look out for" at the LuxLive show.

These accolades contributed to a high level of interest in Nanoco and Marl's stand at the show, along with a number of potential new business opportunities.

The lighting products for ambient and specialty lighting displayed at the show included light-emitting ceiling tiles that create diffuse, artificial daylight with a colour temperature of 6500k and low power consumption. These tiles have outstanding colour performance and are ideally suited to high end retail, healthcare and commercial applications.

The CFQD® Quantum Dot strip lights shown at LuxLive are particularly suited to architectural lighting applications and the down lights offer high end retailers the opportunity to showcase their merchandise under perfect lighting conditions.

Two versions of Nanoco and Marl's grow lights for horticultural applications were also showcased at LuxLive. These grow lights benefit from cadmium-free quantum dots tuned to the wavelengths of light needed for plant growth, hence saving energy and creating optimum lighting conditions. Nanoco is continuing to develop this grow light technology, for example by creating quantum dot films for specific types of plants.

Michael Edelman, Nanoco's CEO, commented: "We were delighted by the level of interest at LuxLive in the use of our cadmium-free quantum dot technology in lighting applications. We were also excited by the interest in the range of products that we have created alongside our partner Marl International.

"LEDs were by far the dominant lighting type at LuxLive, reflecting the compelling attractions of LEDs in the future of lighting. Our technology has the ability to add outstanding colour performance to the other benefits of LEDs, particularly energy efficiency."

For further information, please contact:

Nanoco	Tel: +44 (0) 161 603 7900
Michael Edelman, Chief Executive Officer
David Blain, Chief Financial Officer Caroline Watson, Investor Relations Manager cwatson@nanocotechnologies.com	Tel: + 44 (0) 7799 897357

Canaccord Genuity – Joint Broker	Tel: +44 (0) 20 7523 8000
Simon Bridges
Cameron Duncan Mark Whitmore

Liberum – Joint Broker	Tel: +44 (0) 20 3100 2000
Neil Patel
Richard Bootle Steven Tredget

Buchanan	Tel: +44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Stephanie Watson

Notes for editors:

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nanomaterials for use in multiple applications including LCD displays, lighting, solar cells and bio-imaging. In the display market, it has an exclusive manufacturing and marketing licensing agreement with The Dow Chemical Company.

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocotechnologies.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRABFBBTMBATTMA

Close

27 NOVEMBER 2015

Mission Marketing : Acquisition of Chapter Agency Limited

RNS Number : 1411H The Mission Marketing Group PLC 27 November 2015 The Mission Marketing Group plc Acquisition of Chapter Agency Limited The Mission Marketing Group plc ('the missiontm', "the Company", AIM: TMMG), the marketing communications and advertising group, is pleased to announce that it……

26 NOVEMBER 2015

Netcall PLC : Contract Win

RNS Number : 9967G Netcall PLC 26 November 2015 RNS Reach NETCALL PLC ("Netcall", the "Company" or the "Group") Contract Win First Liberty Customer Experience Manager contract with a Local Authority Netcall plc (AIM: NET), a leading customer engagement software provider, is pleased to announce that it……

10 NOVEMBER 2015

365 Agile Group PLC : Launch of new IoT solutions

RNS Number : 1135F 365 Agile Group PLC 10 November 2015 365 Agile Group plc ("365 Agile" or "the Company") Launch of new IoT solutions 365 Agile is pleased to announce the launch of three new Internet of Things ("IoT") based solutions designed specifically for the Social Housing……

RNS Number : 1135F

365 Agile Group PLC

10 November 2015

365 Agile Group plc

("365 Agile" or "the Company")

Launch of new IoT solutions

365 Agile is pleased to announce the launch of three new Internet of Things ("IoT") based solutions designed specifically for the Social Housing and Care & Support sectors.

The first solution, 365 Agile's 'Smart Heating Control' enables households to have access to cutting edge technology to control the heating in their homes and to gain greater visibility and control on their use of energy from a smart phone or tablet. The smart heating control unit is designed to be easily retro-fitted in just a few minutes by replacing existing standard controllers. The smart unit also provides predictive maintenance alerts to report when a boiler is not working properly and requires maintenance allowing customers to choose a convenient time for preventative maintenance rather than having to wait until the heating system fails. The advanced option also includes full zonal control using thermostatic radiator valves which are easily fitted to existing radiators. The technology should allow users to achieve savings on energy expenditure and will enable Social Housing organisations to significantly reduce operation maintenance costs whilst improving customer service.

The second solution, the Assisted Living suite, is designed to provide advanced levels of care and support to vulnerable customers through the use of 365 Agile's range of smart sensors. The solution will allow non-invasive monitoring of customer behaviour and will provide alerts and tasks in the event that someone needs assistance. The sensors stream real-time data back to the 365 Agile platform and information can be shared with family members as well as care providers. 365 Agile has also been collaborating with Tunstall Healthcare, a leading provider of healthcare solutions, to provide cutting edge solutions to customers that enhance service and provide improved levels of care and support.

The third solution is focused on security with 365 Agile's smart sensors being installed to deliver a low-cost home security pack which will monitor movement, temperature and doors and windows and provide alerts to the customer.

365 Agile already has over 50,000 downloads across the UK and Europe and these new solutions provide a revolutionary new way of delivering services to the Social Housing and Care & Support sectors. 365 Agile has been working closely with Microsoft and has architected the solutions based on the Microsoft Azure stack. The solutions mark the first of a range of 'shrink-wrapped' solutions from 365 Agile that will reduce cost, improve customer service and streamline processes. The new solutions will be available to the Social Housing sector through technology business partner Castleton Technology.

365 Agile is launching the solutions at Microsoft's Future Decoded 2015 at ExCeL London on 10th &11th November.

Jonathan Holyhead, CEO of 365Agile commented:

"365Agile's platform creates a powerful combination that will dramatically transform service delivery. The initial set of smart solutions are being rolled out to the Social Housing and Care & Support sectors and will enable organisations to reduce cost, improve customer service and streamline processes. We have worked closely with Microsoft in the UK and have leveraged the power and scale of Azure with their team to create truly unique solutions that will deliver real benefits and positive change to both organisations and tenants."

Contacts:

365 Agile Group plc	+44 (0)345 50 40 365
Jonathan Holyhead, CEO
finnCap Limited	+44 (0)20 7220 0500
Geoff Nash/Scott Mathieson MXC Capital Advisory LLP Marc Young/ Charlotte Stranner	+44 (0)20 7965 8149

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCDGBDBBUGBGUC

Close

10 NOVEMBER 2015

Nanoco Group PLC : Presentation at LuxLive and Strategies in Light

RNS Number : 1775F Nanoco Group PLC 10 November 2015 This release replaces the RNS Reach announcement released at 7am this morning due to an issue with the LuxLive website link in the earlier release. For immediate release 10 November 2015 RNS REACH NANOCO GROUP……

05 NOVEMBER 2015

Oxford Pharmascience : Successful Completion of PoC for OXPzero Ibuprofen

RNS Number : 6225E Oxford Pharmascience Group PLC 05 November 2015 Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company") Successful Completion of Proof-of-Concept for OXPzeroTM Ibuprofen Following the successful completion of the second study with OXPzeroTM Ibuprofen, the Company is pleased to announce that it has……

RNS Number : 6225E

Oxford Pharmascience Group PLC

05 November 2015

Oxford Pharmascience Group plc

("Oxford Pharmascience" or the "Company")

Successful Completion of Proof-of-Concept for OXPzeroTM Ibuprofen

Following the successful completion of the second study with OXPzeroTM Ibuprofen, the Company is pleased to announce that it has established a robust body of data which it will use to progress into partnering discussions for the application of the Company's OXPzeroTM technology to ibuprofen.

The body of data collected across the two studies demonstrate that OXPzeroTM Ibuprofen is a differentiated, superior form of ibuprofen delivering a range of benefits over the standard drug across multiple parameters. In particular, OXPzeroTM Ibuprofen has been proven to:

– deliver major reduction in the incidence and severity of gastrointestinal (GI) mucosal damage;

– completely taste mask the bitterness of ibuprofen; and

– deliver an attractive PK profile with immediate and complete drug release.

The Company believes these benefits offer major competitive advantages and strongly position OXPzeroTM Ibuprofen to become a disruptive compound in the worldwide ibuprofen market. Ibuprofen is currently the dominant NSAID molecule in the pain relief and anti-inflammatory sector with worldwide sales of Ibuprofen in excess of $4bn per annum. The Company has initiated contact with a number of large, global pharmaceutical companies with strategic interest in the ibuprofen market and is at an advanced stage of preparing information to proceed to the commercialisation phase with the OXPzeroTM Ibuprofen asset.

Marcelo Bravo, Chief Executive Officer, commented:

"We are very pleased with the data package on OXPzeroTM Ibuprofen which demonstrates this is a compound with potential to disrupt the market, delivering a range of key benefits that provide clear and compelling differentiation. The body of data shows this is a versatile and flexible technology that can allow major brand owners to create and sustain competitive advantage in the large and growing ibuprofen market through multiple brand extension options. In the coming weeks, we will be completing preparation of commercial discussion materials with the aim of seeking a partner for the OXPzeroTM Ibuprofen platform. We look forward to updating shareholders in due course.

We continue making great progress with other key NSAIDs, namely OXPzeroTM Naproxen, OXPzeroTM Diclofenac and OXPzeroTM Aspirin and also evaluating further targets. Additional announcements will be made as appropriate."

Background

The Company has conducted two proof-of-concept studies with OXPzeroTM Ibuprofen, each performed with average prescription doses of ibuprofen (2 x 400mg tablets three times per day i.e. 2.4g per day) in healthy subjects:

· Study 1 – OXP001-002: (performed and reported in 2014) PK and endoscopy study with a standard oral 400 mg tablet with OXPzeroTM Ibuprofen vs. Brufen® in 43 healthy subjects.

· Study 2 – OXP001-003: Two part study. Part 1 PK study in 10 healthy subjects reported in August 2015. Part 2 PK and endoscopy study in 43 healthy subjects commenced in August 2015 and now complete. Both parts of the study were performed with a chewable tablet of optimised OXPzeroTM Ibuprofen vs. Brufen®. PK assessments after single dose in Part 1. In Part 2, PK assessments were made on Days 1 and 7 with endoscopy assessments on Day 8.

Endoscopy data confirms major reduction in the incidence and severity of GI mucosal damage

Data from both studies show a consistent, positive trend for OXPzeroTM Ibuprofen through a reduction in the incidence and severity of GI mucosal damage when compared to the Brufen reference.

– OXPzeroTM Ibuprofen exhibited major reductions in the incidence of severe GI mucosal damage (Lanza score ≥3) vs Brufen® ranging from 59% in Study 1 to 36% in Study 2. These are large reductions in the "severe" end of the Lanza scale, namely subjects with over 10 erosions and/or ulcers, demonstrating a clear impact for OXPzeroTM Ibuprofen. Based on odds ratios of 0.16 and 0.43, there is 5.9 to 2.2 times greater likelihood of having Lanza ≥ 3 in the Brufen® group than in the OXPzeroTM Ibuprofen group.

– OXPzeroTM Ibuprofen reduces the odds of a higher Lanza score by approximately 50% to 80% based on odds ratios of 0.17 and 0.46.

– OXPzeroTM Ibuprofen exhibited reductions in the overall mean Lanza score by between 0.9 (p = 0.006) in Study 1 and 0.3 (p = 0.185) in Study 2.

Between Study 1 and Study 2, the comparator Brufen® arm exhibited the biggest changes in absolute levels of GI irritation, with a reduction observed in the second study compared to the first. This demonstrates the variance in these relatively small studies which accounts for the loss of statistical significance in the endoscopy endpoint measures in the second study. Endoscopy efficacy measures were comparable between the OXPzeroTM Ibuprofen products tested in both studies. Further, the lack of correlation between PK (AUC, Cmax, Tmax) and GI damage across studies and treatment groups was confirmed, indicating that the GI irritation reduction seen in Study 1 was not PK dependent, validating the reduction in GI mucosal damage results seen in study 1.

The Company is of the view that the data overall demonstrates that OXPzeroTM Ibuprofen is delivering major reduction in GI mucosal damage and presents an attractive profile for commercialisation.

Superior taste masking

The taste masking benefit of OXPzeroTM Ibuprofen was demonstrated using subject interviews with the chewable tablet of ibuprofen during Study 2. Consistent feedback was received confirming that the chewable tablets were tasteless, with little of the burn or after-taste issues associated with standard ibuprofen. 90% of subjects stated that there was no bitter taste after chewing the OXPzeroTM Ibuprofen tablets. These results highlight the ability of the OXPzeroTM technology to taste mask the ibuprofen by trapping it within the layers of the OXPzeroTM matrix until the drug is released in the stomach.

Attractive PK Profile

PK results from Study 2 show complete and rapid drug release with prolonged T1/2 (the time taken to reach half of peak concentration). PK data also show Tmax (time to reach maximum serum concentration) and AUC (Area Under the Curve or total drug exposure over time) comparable to Brufen®, confirming that OXPzeroTM Ibuprofen used in Study 2 is a product with immediate and complete drug release characteristics. While the PK profile of OXPzeroTM Ibuprofen is comparable to Brufen® on these measures, the maximum level of drug concentration in plasma (Cmax) is lower than that of Brufen®, but well within the therapeutic range.

The data also demonstrate that the release properties can be adapted and the Company believes that the OXPzeroTM platform technology offers the ability to adjust speed of release to meet specific product requirements. The Company believes this is an attractive PK profile with clinical advantage suitable for commercialisation.

* The modified Lanza Scale is a scoring system commonly used to describe the severity of damage to the upper gastro-intestinal tract. The scale in this study was: Score 0 = no damage; 1 = single erosion; 2 = 2 to 9 erosions; 3 = 10 or more erosions; 4 = ulcer. Ulcers were defined as mucosal breaks of 3mm or more demonstrating unequivocal depth.

For further information:

Oxford Pharmascience Group Plc
Marcelo Bravo, Chief Executive	+44 20 7554 5875

N+1 Singer (Nominated Adviser & Broker)
Aubrey Powell/Jen Boorer	+44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.

NSAIDs are one of the most widely used classes of drugs, with combined annual sales in excess of $12bn and more than 30 million users worldwide consuming NSAIDs each day. Ibuprofen is currently the dominant NSAID molecule in the pain relief and anti-inflammatory sector. Worldwide sales of Ibuprofen are in excess of $4bn per annum at manufacturers selling prices. Chronic use of NSAIDs causes well-documented GI side effects, including ulcers and bleeding, and leads to significant morbidity and mortality in a substantial number of patients, with significant associated healthcare costs. The OXPzero™ platform technology reduces these risks and is being selectively applied to the most commonly used NSAID molecules, namely ibuprofen, naproxen and diclofenac for pain and inflammation and aspirin for primary and secondary prevention of cardiovascular disease.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCBIBLTMBIMBMA

Close

03 NOVEMBER 2015

Avanti Comms Group : Contract Win: Telkom SA

RNS Number : 2713E Avanti Communications Group Plc 03 November 2015 3 November 2015 AVANTI COMMUNICATIONS GROUP PLC Telkom SA Contract Win Avanti Communications Group plc ("Avanti" or "the Group"), a leading provider of satellite data communications services in Europe, the Middle East and Africa,……

02 NOVEMBER 2015

Neville Registrars welcomes London Finance & Investment Group P.L.C.

Neville Registrars is delighted to welcome London Finance & Investment Group P.L.C. as the newest addtion to its list of client companies. London Finance & Investment Group is a United Kingdom investment finance and management company listed on the London (Sterling Share Price) and Johannesburg (South African Rand Share Price) Stock Exchanges. Further……

02 NOVEMBER 2015

First Derivatives : Contract win with National Stock Exchange of India

RNS Number : 0978E First Derivatives PLC 02 November 2015 First Derivatives plc ("FD" or the "Company") Contract win with National Stock Exchange of India (NSE) FD (AIM:FDP.L, ESM:FDP.I), a leading provider of software and consulting services, is pleased to announce a contract win with the……

29 OCTOBER 2015

Fastjet PLC : fastjet Zimbabwe's inaugural flight

RNS Number : 8380D Fastjet PLC 29 October 2015 fastjet Plc ("fastjet" or the "Company") 29 October 2015 fastjet Zimbabwe's inaugural flight fastjet (AIM:FJET), Africa's low-cost airline, is pleased to confirm that the first flight of its subsidiary fastjet Zimbabwe, between Harare and Victoria Falls, took place yesterday.……

Enquiries:
The Mission Marketing Group plc	020 7462 1415
David Morgan, Chairman Peter Fitzwilliam, Finance Director

finnCap Limited	020 7220 0500
Geoff Nash/James Thompson (Corporate Finance) Stephen Norcross (Corporate Broking)

Netcall plc	Tel. +44 (0) 330 333 6100
Henrik Bang, CEO Michael Jackson, Chairman James Ormondroyd, Group Finance Director

finnCap Limited (Nominated Adviser and Broker)	Tel. +44 (0) 20 7220 0500
Stuart Andrews / James Thompson, Corporate Finance
Simon Johnson, Corporate Broking

Alma PR	Tel.: +44 (0) 20 7796 9085
Hilary Buchanan / Caroline Forde

First Derivatives plc	+44(0)28 3025 2242
Brian Conlon, Chief Executive Officer	www.firstderivatives.com
Graham Ferguson, Finance Director Ian Mitchell, Head of Investor Relations

Investec Bank plc (Nominated Adviser and Broker)	+44 (0)20 7597 4000
Dominic Emery
Carlton Nelson Sebastian Lawrence

Goodbody (ESM Adviser and Broker)	+353 1 667 0420
Linda Hickey Finbarr Griffin

Walbrook PR	+44 (0)20 7933 8780
Paul Cornelius/ Nick Rome/ Helen Cresswell/ Sam Allen

fastjet Plc	Tel: +44 (0) 20 3651 6307
Ed Winter, Chief Executive Officer
Rose Herbert, Investor Relations Manager

UK media – Citigate Dewe Rogerson	Tel: +44 (0) 20 7638 9571
Angharad Couch
Eleni Menikou
Nick Hayns

South African media – Tribeca Public Relations	Tel: +27 (0) 11 208 5500
Cian Mac Eochaidh
Kelly Webster

For investor enquiries please contact:

Liberum Capital Limited – Nominated Adviser and Joint Broker	Tel: +44 (0) 20 3100 2222
Clayton Bush
Christopher Britton

W.H. Ireland Ltd.- Joint Broker	Tel: +44 (0) 20 7220 1666
James Joyce
Mark Leonard

Sanlam Securities UK Limited – Joint Broker	Tel: +44 (0) 20 7628 2200
Simon Clements/Ken Williams